779 related articles for article (PubMed ID: 25744203)
1. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
[TBL] [Abstract][Full Text] [Related]
2. Activated T cells express the OX40 ligand: requirements for induction and costimulatory function.
Mendel I; Shevach EM
Immunology; 2006 Feb; 117(2):196-204. PubMed ID: 16423055
[TBL] [Abstract][Full Text] [Related]
3. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.
Kondo K; Okuma K; Tanaka R; Zhang LF; Kodama A; Takahashi Y; Yamamoto N; Ansari AA; Tanaka Y
Hum Immunol; 2007 Jul; 68(7):563-71. PubMed ID: 17584577
[TBL] [Abstract][Full Text] [Related]
4. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
5. Rapid induction of OX40 ligand on primary T cells activated under DNA-damaging conditions.
Kondo K; Okuma K; Tanaka R; Matsuzaki G; Ansari AA; Tanaka Y
Hum Immunol; 2008 Sep; 69(9):533-42. PubMed ID: 18718855
[TBL] [Abstract][Full Text] [Related]
6. Blockade of the OX40/OX40L pathway and induction of PD-L1 synergistically protects mouse islet allografts from rejection.
Li T; Ma R; Zhu J; Wang F; Huang L; Leng X
Chin Med J (Engl); 2014; 127(14):2686-92. PubMed ID: 25043090
[TBL] [Abstract][Full Text] [Related]
7. Negative regulation of IL-17 production by OX40/OX40L interaction.
Li J; Li L; Shang X; Benson J; Merle Elloso M; Schantz A; Bracht M; Orlovsky Y; Sweet R
Cell Immunol; 2008; 253(1-2):31-7. PubMed ID: 18501882
[TBL] [Abstract][Full Text] [Related]
8. OX40 ligand is inhibitory during the effector phase of crescentic glomerulonephritis.
Odobasic D; Ruth AJ; Oudin V; Kitching AR; Holdsworth SR
Nephrol Dial Transplant; 2019 Mar; 34(3):429-441. PubMed ID: 29939347
[TBL] [Abstract][Full Text] [Related]
9. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant effect of plasmid vector-expressed OX40L on candidate DNA vaccine against type B heptatitis].
Du X; Kang Y; Wang X; Wang J; Zhao G; Wang B
Wei Sheng Wu Xue Bao; 2009 Mar; 49(3):357-62. PubMed ID: 19623960
[TBL] [Abstract][Full Text] [Related]
11. OX40 ligand regulates splenic CD8⁻ dendritic cell-induced Th2 responses in vivo.
Kamachi F; Harada N; Usui Y; Sakanishi T; Ishii N; Okumura K; Miyake S; Akiba H
Biochem Biophys Res Commun; 2014 Feb; 444(2):235-40. PubMed ID: 24462862
[TBL] [Abstract][Full Text] [Related]
12. A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen.
Kinnear G; Wood KJ; Fallah-Arani F; Jones ND
J Immunol; 2013 Aug; 191(3):1465-75. PubMed ID: 23817421
[TBL] [Abstract][Full Text] [Related]
13. Serial OX40 engagement on CD4+ T cells and natural killer T cells causes allergic airway inflammation.
Damayanti T; Kikuchi T; Zaini J; Daito H; Kanehira M; Kohu K; Ishii N; Satake M; Sugamura K; Nukiwa T
Am J Respir Crit Care Med; 2010 Apr; 181(7):688-98. PubMed ID: 20019337
[TBL] [Abstract][Full Text] [Related]
14. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.
Ishii N; Takahashi T; Soroosh P; Sugamura K
Adv Immunol; 2010; 105():63-98. PubMed ID: 20510730
[TBL] [Abstract][Full Text] [Related]
15. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
[TBL] [Abstract][Full Text] [Related]
16. OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity.
Soroosh P; Ine S; Sugamura K; Ishii N
J Immunol; 2006 May; 176(10):5975-87. PubMed ID: 16670306
[TBL] [Abstract][Full Text] [Related]
17. Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation.
Wang HC; Klein JR
J Immunol; 2001 Dec; 167(12):6717-23. PubMed ID: 11739485
[TBL] [Abstract][Full Text] [Related]
18. The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.
Nuebling T; Schumacher CE; Hofmann M; Hagelstein I; Schmiedel BJ; Maurer S; Federmann B; Rothfelder K; Roerden M; Dörfel D; Schneider P; Jung G; Salih HR
Cancer Immunol Res; 2018 Feb; 6(2):209-221. PubMed ID: 29321210
[TBL] [Abstract][Full Text] [Related]
19. Soluble OX40L favors tumor rejection in CT26 colon carcinoma model.
Serebrovskaya EO; Yuzhakova DV; Ryumina AP; Druzhkova IN; Sharonov GV; Kotlobay AA; Zagaynova EV; Lukyanov SA; Shirmanova MV
Cytokine; 2016 Aug; 84():10-6. PubMed ID: 27203665
[TBL] [Abstract][Full Text] [Related]
20. Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
